| General Information of Drug Metabolite (DM) (ID: DM004997) |
| DM Name |
Asciminib metabolite M30.5
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
UDP-glucuronosyltransferase 2B17 (UGT2B17)
|
DME0066
|
| Conjugation - Glucuronidation |
ABL001
|
[1] |
|
UDP-glucuronosyltransferase 2B7 (UGT2B7)
|
DME0040
|
| Conjugation - Glucuronidation |
ABL001
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| ABL001 |
DR3459
|
Phase 3 |
Chronic myelogenous leukaemia |
|
|
| References |
| 1 |
Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
